Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
A history of antipsychotic drug development
Autore:
Shen, WW;
Indirizzi:
St Louis Univ, Sch Med, Dept Psychiat, St Louis, MO 63104 USA St Louis Univ St Louis MO USA 63104 Dept Psychiat, St Louis, MO 63104 USA
Titolo Testata:
COMPREHENSIVE PSYCHIATRY
fascicolo: 6, volume: 40, anno: 1999,
pagine: 407 - 414
SICI:
0010-440X(199911/12)40:6<407:AHOADD>2.0.ZU;2-S
Fonte:
ISI
Lingua:
ENG
Soggetto:
ATYPICAL ANTIPSYCHOTICS; SCHIZOPHRENIA; HALOPERIDOL; TRIAL; RISPERIDONE; CLOZAPINE; ZOTEPINE; PLACEBO;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Social & Behavioral Sciences
Clinical Medicine
Citazioni:
63
Recensione:
Indirizzi per estratti:
Indirizzo: Shen, WW St Louis Univ, Sch Med, Dept Psychiat, 1221 S Grand Blvd, St Louis, MO 63104 USA St Louis Univ 1221 S Grand Blvd St Louis MO USA 63104 O 63104 USA
Citazione:
W.W. Shen, "A history of antipsychotic drug development", COMP PSYCHI, 40(6), 1999, pp. 407-414

Abstract

The history of antipsychotic drug development has had a long and torturouscourse, often based on chance findings that bear little relationship to the intellectual background driving observations. In 1891, Paul Ehrlich observed the antimalarial effects of methylene blue, a phenothiazine derivative. Later, the phenothiazines were developed for their antihistaminergic properties. In 1951, Laborit and Huguenard administered the aliphatic phenothiazine, chlorpromazine, to patients for its potential anesthetic effects during surgery. Shortly thereafter, Hamon et al. and Delay et al. extended the use of this treatment in psychiatric patients and serendipitously uncovered its antipsychotic activity. Between 1954 and 1975, about 15 antipsychotic drugs were introduced in the United States and about 40 throughout the world. Thereafter, there was a hiatus in the development of antipsychotics untilthe introduction of clozapine treatment in the United States in 1990 opened the era of "atypical" antipsychotic drugs, which show a reduced potentialto induce extrapyramidal symptoms (EPS), an increased efficacy for the negative symptoms of schizophrenia, no elevation of prolactin after chronic use (except risperidone), and, at least for clozapine, effectiveness in some patients previously regarded as treatment-refractory. This review describesthe available atypical antipsychotic drugs and their characteristics, and concludes by highlighting those in the pharmaceutical "pipeline. " Copyright(C) 1999 by W.B. Saunders Company.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 18/01/20 alle ore 10:47:19